Login / Register Submit Your Article
cover
Article Menu

Journal Browser
Vol. 2 (2024)
Vol. 1 (2023)
Indexing and Partners

Google scholar

Crossref

Open Access Review

Stability Indicating Double Divisor Spectrophotometric Method for determination of Diloxanide Furoate and Metronidazole in Their Binary Mixture

by Maha M. Abdelrahman 1,* ,  Nouruddin W. Ali 1 ,  Samah S. Abbas 2 ,  Hala E. Zaazaa 2  and  M. Abdelkawy 2
1
Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-Suef University, Alshaheed Shehata Ahmed Hegazy St. Beni-Suef 62514, Egypt.
2
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr-El-Aini St., 11562, Cairo, Egypt.
*
Author to whom correspondence should be addressed.
IJCMR  2023, 8; 1(2), 8; https://doi.org/10.61466/ijcmr1020008
Received: 18 July 2023 / Accepted: 16 September 2023 / Published Online: 19 September 2023
View Full-Text
Download PDF

Abstract

Diloxanide furoate (DXF) and Metronidazole (MTZ) are commonly combined as a binary mixture for the treatment of a variety of diseases brought on by bacteria and parasites including amoebiasis and giardiasis. Different analytical methods were established for determination of both DXF and MTZ, However, only one chemometric spectrophotometric method was established for their stability indicating determination which involves problematical steps and specific software program. Herein, double divisor ratio spectra derivative (DDRSD) method is exploited for quantification of DXF and MTZ in presence of DXF-degradation products (FUR and DEG). The recommended DDRSD method is linear over the range of 2–25 and 1–25 µg/mL for DXF and MTZ, correspondingly. Additionally, the suggested method was effectively employed to their pharmaceutical formulations with good findings. Besides, the recommended DDRSD method was validated conforming to ICH guidelines. The introduced DDRSD method is simple, selective, and economic and could be implemented for quality control samples of the studied drugs.

Keywords: Diloxanide furoate; Metronidazole; Double Divisor spectrophotometry, Method validation;
Copyright: © 2023 by Abdelrahman, Ali, Abbas, Zaazaa and Abdelkawy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Share and Cite

ACS Style
Abdelrahman, M. M.; Ali, N. W.; Abbas, S. S.; Zaazaa, H. E.; Abdelkawy, M. Stability Indicating Double Divisor Spectrophotometric Method for determination of Diloxanide Furoate and Metronidazole in Their Binary Mixture. International Journal of Clinical Medical Research, 2023, 1, 8. https://doi.org/10.61466/ijcmr1020008
AMA Style
Abdelrahman M M, Ali N W, Abbas S S, Zaazaa H E, Abdelkawy M. Stability Indicating Double Divisor Spectrophotometric Method for determination of Diloxanide Furoate and Metronidazole in Their Binary Mixture. International Journal of Clinical Medical Research; 2023, 1(2):8. https://doi.org/10.61466/ijcmr1020008
Chicago/Turabian Style
Abdelrahman, Maha M.; Ali, Nouruddin W.; Abbas, Samah S.; Zaazaa, Hala E.; Abdelkawy, M. 2023. "Stability Indicating Double Divisor Spectrophotometric Method for determination of Diloxanide Furoate and Metronidazole in Their Binary Mixture" International Journal of Clinical Medical Research 1, no.2:8. https://doi.org/10.61466/ijcmr1020008

Article Metrics

Article Access Statistics

References

  1. [1] F. P. Tally and C. E. Sullivan, “Metronidazole: in vitro activity, pharmacology and efficacy in anaerobic bacterial infections,” Pharmacother. J. Hum. Pharmacol. Drug Ther., vol. 1, no. 1, pp. 28–38, 1981.
  2. [2] A. A. Al-Majed, F. Belal, and A. A. Al-Badr, “Diloxamde furoate,” in Analytical profiles of drug substances and excipients, vol. 26, Elsevier, 1999, pp. 247–282.
  3. [3] H. Qureshi, A. Ali, R. Baqai, and W. Ahmed, “Efficacy of a Combined Diloxanide Furoate—Metronidazole Preparation in the Treatment of Amoebiasis and Giardiasis,” J. Int. Med. Res., vol. 25, no. 3, pp. 167–170, 1997.
  4. [4] M. R. El-Ghobashy and N. F. Abo-Talib, “Spectrophotometric methods for the simultaneous determination of binary mixture of metronidazole and diloxanide furoate without prior separation,” J. Adv. Res., vol. 1, no. 4, pp. 323–329, 2010.
  5. [5] M. M. Issa, A. M. A. Shanab, and N. T. Shaat, “Kinetic spectrophotometric H-point standard addition method for the simultaneous determination of diloxanide furoate and metronidazole in binary mixtures and biological fluids,” Spectrochim. Acta Part A Mol. Biomol. Spectrosc., vol. 114, pp. 592–598, 2013.
  6. [6] N. H. Al Shaalan, “Determination of diloxanide furoate and metronidazole in binary mixture using first derivative of the ratio-spectra and highperformance liquid chromatography-UV methods,” J Appl Sci, vol. 4, pp. 66–72, 2007.
  7. [7] M. M. Elkhoudary, R. A. A. Salam, and G. M. Hadad, “Comparative artificial neural network and partial least squares models for analysis of Metronidazole, Diloxanide, Spiramycin and Cliquinol in pharmaceutical preparations,” Spectrochim. Acta Part A Mol. Biomol. Spectrosc., vol. 130, pp. 222–229, 2014.
  8. [8] S. M. Galal, M. M. Bedair, and M. A. El-Sayed, “Derivative spectrophotometric determination of antiprotozoal drugs in two-component tablet preparation.,” J. Pharm. Belg., vol. 46, no. 5, pp. 315–319, 1991.
  9. [9] S. S. Abbas, N. E. Wagieh, M. Abdelkawy, and M. M. Abdelrahman, “Simultaneous determination of diloxanide furoate and metronidazole in presence of diloxanide furoate degradation products,” J. AOAC Int., vol. 94, no. 5, pp. 1427–1439, 2011, doi: 10.5740/jaoacint.10-286.
  10. [10] E. A. Abdelaleem and N. S. Abdelwahab, “Validated chromatographic and spectrophotometric methods for analysis of some amoebicide drugs in their combined pharmaceutical preparation.,” Pak. J. Pharm. Sci., vol. 26, no. 1, 2013.
  11. [11] S. K. Talwar, S. C. Sharma, and S. Das, “Simultaneous spectrophotometric determination of diloxanide furoate and metronidazole in dosage forms,” J. Pharm. Biomed. Anal., vol. 4, no. 4, pp. 511–515, 1986.
  12. [12] M. M. Elkhoudary, R. A. Abdel Salam, and G. M. Hadad, “Development and optimization of HPLC analysis of metronidazole, diloxanide, spiramycin and cliquinol in pharmaceutical dosage forms using experimental design,” J. Chromatogr. Sci., vol. 54, no. 10, pp. 1701–1712, 2016.
  13. [13] K. R. Danao, S. M. Hiradere, R. S. Moon, A. V Kasture, and P. G. Yeole, “RP-HPLC simultaneous estimation of metronidazole and diloxanide furoate in combination,” Int J pharm life Sci, vol. 1, pp. 82–85, 2010.
  14. [14] S. M. El-Gizawy, “HPLC analysis of metronidazole and diloxanide furoate in its dosage forms,” Anal. Lett., vol. 28, no. 1, pp. 83–92, 1995.
  15. [15] A. Mishal and D. Sober, “Stability indicating reversed-phase liquid chromatographic determination of metronidazole benzoate and diloxanide furoate as bulk drug and in suspension dosage form,” J. Pharm. Biomed. Anal., vol. 39, no. 3–4, pp. 819–823, 2005.
  16. [16] M. M. Morcoss, N. S. Abdelwahab, N. W. Ali, and M. T. Elsaady, “Different chromatographic methods for simultaneous determination of diloxanide furoate, metronidazole and its toxic impurity,” J. Iran. Chem. Soc., vol. 13, pp. 1643–1651, 2016.
  17. [17] M. Mabrouk, H. El-Fatatry, I. Hewala, and E. Emam, “Development and application of a novel, dual-mode gradient, stability-indicating HPLC-DAD method for the simultaneous determination and purity assessment of mebeverine hydrochloride, diloxanide furoate and their corresponding major degradation products in,” J. Pharm. Biomed. Anal., vol. 83, pp. 249–259, 2013.
  18. [18] E. A. Bahgat, M. S. Elmasry, and R. A. Sayed, “The application of experimental design and green analytical chemistry in HPLC strategy for the determination of five drugs used in antimicrobial combination therapy,” Microchem. J., p. 108915, 2023.
  19. [19] E. A. Abdelaleem and N. S. Abdelwahab, “Simultaneous determination of some antiprotozoal drugs in their binary and ternary mixtures with mebeverine hydrochloride in different dosage forms,” J. Liq. Chromatogr. Relat. Technol., vol. 36, no. 11, pp. 1528–1539, 2013.
  20. [20] E. Dinç, “The spectrophotometric multicomponent analysis of a ternary mixture of ascorbic acid, acetylsalicylic acid and paracetamol by the double divisor-ratio spectra derivative and ratio spectra-zero crossing methods,” Talanta, vol. 48, no. 5, pp. 1145–1157, 1999.
  21. [21] S. Pandey, N. K. Karmakar, R. K. Pandey, and S. S. Shukla, “A double divisor ratio-spectra derivative method for the ternary mixture of aspirin, clopidogrel bisulphate and rosuvastatin calcium,” Anal. Chem. Lett., vol. 11, no. 5, pp. 696–707, 2021.
  22. [22] S. H. Elagamy, “Resolving Problems Encountered in Spectrophotometric Analysis of a Ternary Mixture of Linagliptin, Empagliflozin and Metformin Hydrochloride,” Anal. Chem. Lett., vol. 12, no. 3, pp. 349–357, 2022.
  23. [23] E. Dinç, E. Baydan, M. Kanbur, and F. Onur, “Spectrophotometric multicomponent determination of sunset yellow, tartrazine and allura red in soft drink powder by double divisor-ratio spectra derivative, inverse least-squares and principal component regression methods,” Talanta, vol. 58, no. 3, pp. 579–594, 2002.
  24. [24] R. Hajian and A. Soltaninezhad, “The spectrophotometric multicomponent analysis of a ternary mixture of paracetamol, aspirin, and caffeine by the double divisor-ratio spectra derivative method,” J. Spectrosc., vol. 2013, 2013.
  25. [25] H. Salem, H. M. Lotfy, N. Y. Hassan, M. B. El-Zeiny, and S. S. Saleh, “A comparative study of different aspects of manipulating ratio spectra applied for ternary mixtures: derivative spectrophotometry versus wavelet transform,” Spectrochim. Acta Part A Mol. Biomol. Spectrosc., vol. 135, pp. 1002–1010, 2015.
  26. [26] M. Bakshi and S. Singh, “Development of validated stability-indicating assay methods—critical review,” J. Pharm. Biomed. Anal., vol. 28, no. 6, pp. 1011–1040, 2002.
  27. [27] S. S. Abbas, H. E. Zaazaa, M. Abdelkawy, and M. M. Abdelrahman, “Spectrophotometric determination of isopropamide Iodide and trifluoperazine hydrochloride in presence of trifluoperazine oxidative degradate,” Drug Test. Anal., vol. 2, no. 4, pp. 168–181, 2010.
  28. [28] R. M. Maggio, S. E. Vignaduzzo, and T. S. Kaufman, “Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations,” TrAC Trends Anal. Chem., vol. 49, pp. 57–70, 2013.
  29. [29] H. E. Zaazaa, M. M. Abdelrahman, N. W. Ali, M. A. Magdy, and M. Abdelkawy, “Kinetic study and mechanism of Niclosamide degradation,” Spectrochim. Acta Part A Mol. Biomol. Spectrosc., vol. 132, pp. 655–662, 2014.
  30. [30] A. Parmar and S. Sharma, “Derivative UV-vis absorption spectra as an invigorated spectrophotometric method for spectral resolution and quantitative analysis: Theoretical aspects and analytical applications: A review,” TrAC Trends Anal. Chem., vol. 77, pp. 44–53, 2016.
  31. [31] A.-A. Y. El-Sayed and N. A. El-Salem, “Recent developments of derivative spectrophotometry and their analytical applications,” Anal. Sci., vol. 21, no. 6, pp. 595–614, 2005.
  32. [32] M. M. Abdelrahman, I. A. Naguib, M. R. El Ghobashy, and N. A. Ali, “Quantitative determination of zopiclone and its impurity by four different spectrophotometric methods,” Spectrochim. Acta Part A Mol. Biomol. Spectrosc., vol. 137, pp. 617–624, 2015.
  33. [33] ICH, “Validation of an analytical Procedures : text and methodology Q2(R1),” Guidance, vol. 1994, no. November 1996, p. 17, 2005.